Tjandra J J, Lim J F, Hiscock R, Rajendra P
Department of Colorectal Surgery, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
Dis Colon Rectum. 2004 Dec;47(12):2138-46. doi: 10.1007/s10350-004-0760-3.
Fecal incontinence caused by a weak or disrupted internal anal sphincter is common but there has been no effective treatment. This prospective study evaluates the medium-term clinical effects of an injectable silicone biomaterial, PTP (Bioplastique), used to augment the internal anal sphincter.
Eighty-two patients (64 females; median age, 66 years) with severe fecal incontinence and a low anal resting pressure caused by internal anal sphincter dysfunction (defect, n = 11; intact, n = 71) were randomized to PTP injection into intersphincteric space and internal anal sphincter with (Group A, n = 42) or without (Group B, n = 40) guidance by endoanal ultrasound. Both groups were similar in terms of age, gender, past anorectal surgery, duration of follow-up (median, 6 months; range, 1-12 months), and baseline continence score. Sixty-two percent of Group A and 55 percent of Group B had prolonged pudendal nerve terminal motor latency.
There was no significant complication. Two patients in Group A and four patients in Group B noted minor discomfort at injection sites. At one month postprocedure, endoanal ultrasound confirmed retention of silicone biomaterial without migration. In both groups, fecal continence was significantly improved by PTP implants 1 month after injection, but continued to improve significantly for up to 12 months in Group A and 6 months in Group B (P < 0.001). Improvement in fecal continence and maximum anal resting pressure was significantly greater in Group A, in whom injection was guided by endoanal ultrasound, than in Group B. At three months after injection, significantly more Group A patients than Group B patients achieved >50 percent improvement in Wexner's continence score (69 percent vs. 40 percent; P = 0.014). Ninety-three percent of Group A and 92 percent of Group B had >50 percent improvement in global quality of life scores (visual analog scale). At a median follow-up of 6 months, all domains of the fecal incontinence quality of life scale improved significantly in both groups; however, the physical function and mental health scores of Short Form-12 only improved in Group A. A prolonged pudendal nerve terminal motor latency had no effect on functional outcome in either group.
Injection of silicone biomaterial provided a marked improvement in fecal continence and quality of life in patients with internal sphincter dysfunction, despite the presence of pudendal neuropathy.
因肛门内括约肌薄弱或受损导致的大便失禁很常见,但一直没有有效的治疗方法。本前瞻性研究评估了一种可注射的硅基生物材料PTP(Bioplastique)用于增强肛门内括约肌的中期临床效果。
82例(64例女性;中位年龄66岁)因肛门内括约肌功能障碍导致严重大便失禁且肛门静息压较低的患者(括约肌缺陷11例,完整71例)被随机分为两组,A组(n = 42)在经肛门超声引导下将PTP注入括约肌间隙和肛门内括约肌,B组(n = 40)则无超声引导。两组在年龄、性别、既往肛肠手术史、随访时间(中位6个月;范围1 - 12个月)和基线控便评分方面相似。A组62%和B组55%的患者存在阴部神经终末运动潜伏期延长。
无显著并发症。A组2例患者和B组4例患者在注射部位有轻微不适。术后1个月,经肛门超声证实硅基生物材料保留且无移位。两组在注射后1个月时,PTP植入均使大便失禁情况显著改善,但A组在长达12个月内持续显著改善,B组在6个月内持续显著改善(P < 0.001)。在经肛门超声引导注射的A组,大便失禁和最大肛门静息压的改善显著大于B组。注射后3个月,A组中大便失禁Wexner评分改善>50%的患者显著多于B组(69%对40%;P = 0.014)。A组93%和B组92%的患者总体生活质量评分(视觉模拟量表)改善>50%。中位随访6个月时,两组大便失禁生活质量量表的所有领域均显著改善;然而,简式健康调查12项中的身体功能和心理健康评分仅在A组有所改善。阴部神经终末运动潜伏期延长对两组的功能结局均无影响。
尽管存在阴部神经病变,但注射硅基生物材料能显著改善肛门内括约肌功能障碍患者的大便失禁和生活质量。